Skip to content

Effect of Apples on cardioVascular Risk And Gut Health

Effect of Apples Consumption on Blood Lipid Levels,Vascular Function and Gut Health in Moderate Hypercholesterolemic Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01988389
Acronym
AVAG
Enrollment
40
Registered
2013-11-20
Start date
2013-09-30
Completion date
2014-11-30
Last updated
2015-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Hypercholesterolemia

Brief summary

There is now considerable scientific evidence that a diet rich in fruits and vegetables could improve human health. Apples are among the most frequently consumed fruits in the world. Epidemiological studies have linked frequent apple consumption with several health benefits including a reduced risk of cardiovascular disease. Apples are an important source of polyphenols and fiber and their beneficial effects could be attributed to this content; however, their impact on our health is not clear. Although, there are some studies that have reported cholesterol lowering effects the results are inconsistent. Furthermore, few studies have explored the impact on vascular function and gut microbiota. The objective of the current study is to assess whether a regular apple consumption, reduces total cholesterol levels, improves vascular function and gut microbiota profile in mildly hypercholesterolemic subjects compared with a control, sugar matched commercial clear apple juice squash.

Interventions

DIETARY_SUPPLEMENTwhole apples (WA)
DIETARY_SUPPLEMENTapple juice (AJ)

Sponsors

Fondazione Edmund Mach di San Michele all'Adige
CollaboratorOTHER
University of Reading
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
23 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* Mildly hypercholesterolemic: TC\>5.2 and \<7.9 mmol/L * BMI: 20-35 * Age: 23-69 * Normal liver and kidney function

Exclusion criteria

* Drug treatment for hyperlipidaemia, hypertension, inflammation and hypercoagulation. * Vegetarians. * Smoking. * History of alcohol misuse. * History of food allergy (e.g. apples, sulphites). * Taking antibiotics for the previous 3 months. * Taking phytochemical, antioxidant, fish oil supplements, or prebiotic/probiotic preparations unless willing to stop for the study period and after a 4 week wash out period (8 weeks for fish oil). * Females who are pregnant, lactating, or if of reproductive age and not using a reliable form of contraception (including abstinence). * Medical history of cardiovascular disease including coronary heart disease (angina and heart attack) and stroke (in the past 12 months). * Family history of cardiovascular disease (their father or brother was under 55 or their mother or sister was under 65 when they were diagnosed with cardiovascular disease). * Diabetes mellitus. * Kidney, liver, pancreas or gastrointestinal diseases. * Hematologic disorders (i.e. anaemia; men:haemoglobin\<13.8g/dl (8.56mmol/L) and women\<12.1 g/dl (5.51mmol/L)). * Planning a weight reducing regime. * Parallel participation in another dietary intervention study.

Design outcomes

Primary

MeasureTime frame
Changes in blood lipid levelsBaseline and assessment at 8 weeks for each intervention arm including a 4 week wash out period.

Secondary

MeasureTime frameDescription
Evaluation of endothelial function by using laser doppler iontophoresis (LDI)Baseline and assessment at 8 weeks for each intervention arm.
Changes in vascular stiffness by pulse wave analysis (PWA)Baseline and assessment at 8 weeks for each intervention arm
Changes in faecal bacterial populationBaseline and assessment at 8 weeks for each intervention arm
Changes in insulin resistance and gut hormonesBaseline and assessment at 8 weeks for each intervention arm
Changes in inflammatory, endothelial function and oxidative stress markersBaseline and assessment at 8 weeks for each intervention arm
Metabolomic analysis for the determination of the low molecular weight metabolite profiles in the biological fluids (blood, urine and faecal sample).Baseline and assessment at 8 weeks for each intervention arm
Ambulatory blood pressureBaseline and assessment at 8 weeks for each intervention armBlood pressure will be recorded for 30 minutes at baseline and at 8 weeks for each intervention arm

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026